Challenges Of Enriched Environment Might Curb Cancer Growth  

Share this news item:

Contact Us

For media inquiries:
614-293-3737

To find a doctor, get a referral or for information on a clinical trial:
614-293-5066
or 800-293-5066

Search for a clinical trial

Posted: 7/8/2010

COLUMBUS, Ohio – Living in an environment rich with physical, mental and social stimulation – a setting that causes mild stress – appears by itself to curb cancer growth, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

The animal study, published as the lead cover story of the July 9 issue of the journal Cell, also shows how this effect happens and that it might have therapeutic use.

The researchers discovered that an enriched environment activates a nervous-system pathway used by the brain to talk to fat tissue. That pathway, called the hypothalamic-sympathoneural-adipocyte (HSA) axis tells fat cells to stop releasing a hormone called leptin into the bloodstream. Leptin normally helps restrain appetite, but this study discovered that it also accelerates cancer growth.

The enriched environment had the same cancer-curbing influence in models of melanoma and colon cancer.

“People tend to think that cancer survivors should avoid stress, but our data suggests that this is not completely true,” says study leader Dr. Matthew J. During, professor of neuroscience, of neurological surgery and of molecular virology, immunology and medical genetics.

“The anti-cancer effect we observed in this study was not due simply to increased activity by the animals, but rather it was induced by social and physical challenges that cause mild stress, as measured by the release of hormones from the adrenal.

“But the most dramatic hormonal change we observed was the drop in leptin from fat after enhanced housing conditions activated the HSA pathway. That pathway is also present in humans, where it is likely to be activated by a more complex and challenging life,” he adds.

The enriched environment created for this study housed 20 mice in large containers equipped with toys, hiding places and running wheels, along with unlimited food and water. Control mice were housed in groups of five in smaller, standard laboratory containers with no toys but with unlimited food and water.

The researchers injected human melanoma cells injected under the skin in both sets of animals. After three weeks of enriched housing, mice had tumors that were about half the size of those in control mice. With six weeks of enrichment, those tumors had dropped to about one fifth the size of those in control animals, and almost 20 percent of enriched-group animals had no visible tumors at all. Control animals, on the other hand, all had visible tumors.

Investigating this effect further, During and his colleagues looked for changes in several metabolic hormones in the blood. Of those, leptin showed a dramatic drop in the enriched group.

A series of experiments demonstrated that leptin and the nervous system pathway really did influence tumor growth.

Looking closely at the region of the brain called the hypothalamus, the researchers found that a gene called BDNF, which plays an important role in controlling food intake and energy balance, was much more active in the enriched group.

Transplanting extra copies of this gene into the hypothalamus of mice in standard housing mimicked the effects of the enriched environment and reduced the size of the tumors in these animals by 75 percent. Such an intervention is also possible clinically and could potentially be developed into a human therapeutic. Blocking the gene, on the other hand, cancelled this effect and caused even enriched animals to develop large tumors.

“This is the first time anyone has shown that putting a single gene into the brain could have a dramatic impact on cancer,” During says.

Next, they studied a strain of mice that was unable to make leptin and so lacked the hormone altogether. When they infused these animals with leptin, they developed melanoma tumors that were 40 percent larger than those in similar animals infused with a saline solution.

Finally, an enriched environment had a similar cancer-controlling effect in both of two colon-cancer models. In one of these, tumors develop spontaneously in the intestine; in the other, visible tumors develop after cancer cells are injected under the skin.

Using the second model, researchers discovered that the anti-cancer effect occurred when animals were placed in the enriched environment six days after visible tumors were well established.

“This finding suggests that such an enriched environment might have therapeutic importance,” During says.

During notes that increased physical activity – running in a wheel – alone did not produce the anti-cancer effect or activate the HSA axis. Increased activity did reduce levels of the stress hormone corticosterone in control animals, whereas levels of this hormone rose in animals in enriched housing, an outcome likely due to the challenges and social conflicts associated with larger and more complex group housing.

“Overall, our study suggests that an environmental or genetic activation of this nervous system pathway leads to a marked drop in serum leptin levels, and that this inhibits tumor growth.”

Funding from the National Institute for Neurological Disorders and Stroke supported this research.

Other researchers involved in this study were first and co-corresponding author Lei Cao, as well as Xianglan Liu, En-Ju D Lin, Chuansong Wang, Eugene Choi and Veronique Riban with The Ohio State University; and Benjamin Lin with Weill Medical College of Cornell University.

The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (http://cancer.osu.edu) is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top 20 cancer hospitals in the nation, The James is the 180-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only seven funded programs in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.

###


Related Links:


Darrell Ward
Medical Center Communications
614-293-3737
Darrell.Ward@osumc.edu



Tags: Basic Research

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu